<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EA3B9AB7-23D9-4DF8-87CD-51614A87D13F"><gtr:id>EA3B9AB7-23D9-4DF8-87CD-51614A87D13F</gtr:id><gtr:name>Sixth Framework Programme (FP6)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EA3B9AB7-23D9-4DF8-87CD-51614A87D13F"><gtr:id>EA3B9AB7-23D9-4DF8-87CD-51614A87D13F</gtr:id><gtr:name>Sixth Framework Programme (FP6)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42CE62AA-63C7-447E-8692-AE40469EF4A2"><gtr:id>42CE62AA-63C7-447E-8692-AE40469EF4A2</gtr:id><gtr:firstName>Anatoli</gtr:firstName><gtr:surname>Kamali</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950080930"><gtr:id>48CE784C-E735-4EF2-9921-021524F6280B</gtr:id><gtr:title>HIV Prevention Research Programme / Microbicide Effectiveness Trial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950080930</gtr:grantReference><gtr:abstractText>Women are more vulnerable to HIV infection through heterosexual transmission than men because of biological reasons and because of socio-economic and cultural factors that make negotiation of safer sexual practices difficult. Vaginal microbicides may be effective in preventing the transmission of HIV infection to a women from an infected partner. Vaginal microbicides are chemical substances that may work e.g. by blocking HIV from entering the wall of the vagina or the uterus or by killing the virus. There are a variety of possible microbicide products under investigation.|A large scale trial has been conducted from 2005 2009 by the international Microbicides Development Programme, a collaboration of 6 African research institutions, the MRC Clinical Trials Unit London and Imperial College London. The product to be tested was PRO 2000/5, which had been shown to be effective against HIV when tested in the laboratory, and shown to be safe in several smaller studies. The trial aimed to establish whether this product is effective in preventing HIV infection among HIV-negative women. The trial found that the product was safe to use but was ineffective in providing protection against HIV infection. This result was very disappointing. However it provided conclusive evidence that the type of vaginal microbicide product investigated does not protect HIV negative women against HIV acquisition. Research continues to find a product that is both safe and effective.</gtr:abstractText><gtr:technicalSummary>Objective: To evaluate the efficacy and safety of two concentrations of a vaginal microbicide gel (0.5% and 2% PRO 2000/5) in preventing vaginally acquired HIV infection.|Methods: This trial (MDP-301) was a multi-centre randomised placebo controlled trial involving the MRC/UVRI Uganda Unit and five partner institutions in Tanzania, Zambia and South Africa. The study was coordinated by the MRC Clinical Trials Unit in London and Imperial College London. It was part of the Microbicides Development Programme (MDP) which was funded by the Department for International Development (DFID) and the MRC. The product under investigation was an aqueous gel consisting of a naphthalene sulphonic acid polymer, provided by Indevus Pharmaceuticals Inc. (USA). Its principle safety and acceptability had been evaluated earlier. Primary outcome measures comprised the acquisition of new HIV infection and the occurrence of adverse events. The trial involved 9,385 women enrolled at the six African researh centres. The MRC/UVRI Uganda Research Unit on AIDS enrolled women into the trial who lived in a HIV sero-discordant couple relationship. |The trial began in 2005 and was completed by the end of 2009. The results have recently been communicated. |(see http://www.mdp.mrc.ac.uk; 17th Conference on Retroviruses and Opportunistic Infections 2010, late breaker abstract 87LB)|Results: The trial found that the risk of HIV infection in women who were supplied with PRO 2000 gel was not significantly different than in women supplied with placebo gel. Although ineffective in providing protection, PRO 2000 gel itself was safe to use. This study outcome, whilst disappointing, provided definite evidence that the poly-anion class of vaginal microbicides does not protect HIV negative women against HIV acquisition.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3950655</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sixth Framework Programme (FP6)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>EDCTP</gtr:description><gtr:id>B255D449-0E08-459F-94ED-FBDB6E547C22</gtr:id><gtr:impact>A number of scientific presentations at national and international conferences and publications in peer reviwed journals.</gtr:impact><gtr:outcomeId>GTwAJTWk6yF-1</gtr:outcomeId><gtr:partnerContribution>Strengthening of long term clinical and laboratory research capacity, cohort development, and collection of epidemiological and social science baseline data in Uganda and Malawi to prepare for future HIV vaccine trials.</gtr:partnerContribution><gtr:piContribution>Understanding HIV transmission patterns in fishing communities and its contribution to the HIV epidemic trends in Uganda</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>International AIDS Vaccine Initiative (IAVI)</gtr:description><gtr:id>1EC92799-41BB-4C08-8CC8-223560812725</gtr:id><gtr:impact>Clinical and cell laboratories have been established at the field station, which have been acredited. Staff been trained in GCP/GCLP standards. A vaccine pharmacy has been established to support the forthcoming phase I HIV vaccine trial. The collaboration is multidisciplinary involving Basic Science, Epidemiology and Clinical Medicine.</gtr:impact><gtr:outcomeId>0F3509965DB-1</gtr:outcomeId><gtr:partnerContribution>Training and Infrastructure development</gtr:partnerContribution><gtr:piContribution>Developed an HIV high risk cohort in preparation for HIV vaccine trials. Conducted HIV prevalence and incidence, acute HIV infection studies which are relevant to future HIV vaccine studies and development. 

Condcted a pilot study of Pre-Exposure Prophylaxis (PrEP) to evaluate safety, acceptability, and adherence in at-risk populations in Uganda, Africa. The study is just been completed. We are starting shortly a Phase I double-blinded, placebo-controlled, randomized trial in HIV uninfected,healthy adult volunteers evaluating the safety and
immunogenicity of F4co adjuvanted with AS01B or AS01E administeredwith Ad35-GRIN</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>Microbicide Development Programme (MDP)</gtr:description><gtr:id>A0408ED8-1353-417C-83B4-E5FAD191AABA</gtr:id><gtr:impact>Provided HIV counselling and testing, STI screening and treatment to all particapnts. Presented key findings at international conferences. Final results have just been released and publication plan is underway.</gtr:impact><gtr:outcomeId>EC7997901B6-1</gtr:outcomeId><gtr:partnerContribution>Training and Insfrastructure development</gtr:partnerContribution><gtr:piContribution>We participated and contributed to the design, conduct and data management of the trial. Contributed 840 women to the overall sample size.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Various Press (TV, Radio, and Print)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9B0D25D8-9713-44F6-8FAE-EAF4EFFD134C</gtr:id><gtr:impact>Held a press conference to discuss the findings of the IPM phase III trial. Attracted several journalists from many press houses. Continuous update of our research activities to the media.

Information disseminated through the print and radio/TV media. Final Press conference was attended by senior Ugandan Ministry of health officials including the Minister of health.</gtr:impact><gtr:outcomeId>74B89E80778</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008,2009,2010,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Political leaders</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>65D5F507-8635-465B-9CEA-A0F3B8D6C2E9</gtr:id><gtr:impact>On a regular basis we organise meetings with the local political leadership to up date them on progress of our activities. At national level meetings are held with parliamentarians.

Dissemination and mobilisation of our resarch activities in their respective constituencies.</gtr:impact><gtr:outcomeId>A4831AE76BF</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2008,2009,2010,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HIV Care support organisations, CAB members and wider community</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D0C2516-E281-4F51-A2CF-787F385C38D4</gtr:id><gtr:impact>Continous dissemination to the wider community, Community Advisory Board members, and to our non-acedmic partners such as TASO and other HIV care support organisations. Several hundreds of people reached.

Better support to our research activities, and high retention in our follow up of cohorts.</gtr:impact><gtr:outcomeId>7662EE7DF4E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2335025</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Strengthening of long term clinical and laboratory research capacity, cohort development, and collection of epidemiological and social science baseline data in Uganda and Malawi to prepare for future HIV vaccine trials.</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>B015A3EB-06BE-40F4-B2C7-03823D11792D</gtr:id><gtr:outcomeId>dZrVK6dWz8g0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>910000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>International AIDS Vaccine Initiative (IAVI) Clinical Trial and Laboratory HIV Vaccine Program 2011</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>International AIDS Vaccine Initiative (IAVI)</gtr:fundingOrg><gtr:id>AAE4C52A-4F0F-41A7-A8F1-0900A063E064</gtr:id><gtr:outcomeId>CgjdQ4sUvrw0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>827000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IAVI Clinical Trial and Laboratory Program for 2010</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>International AIDS Vaccine Initiative (IAVI)</gtr:fundingOrg><gtr:id>7BF6B39C-6F42-4D7A-9B8D-C228FCC671EB</gtr:id><gtr:outcomeId>E566F667C200</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2004-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the National Expert Think Tank of the HIV Prevention</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F76E770B-E9E7-42D4-A9E4-3C57B5820001</gtr:id><gtr:impact>To develop a sound and evidence-based HIV Prevention Strategy for Uganda closely linked to the Uganda National Multisectoral HIV/AIDS Strategic Plan.</gtr:impact><gtr:outcomeId>KKkeowv1Kno</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4A3B7ED3-DF5A-423A-A4D4-02BD036382FE</gtr:id><gtr:title>HIV incidence and risk factors for acquisition in HIV discordant couples in Masaka, Uganda: an HIV vaccine preparedness study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c49b143941eab24018db8cab075e832"><gtr:id>1c49b143941eab24018db8cab075e832</gtr:id><gtr:otherNames>Ruzagira E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>ReL2imGkLca</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>341D42FD-C1B1-4ED3-B75D-1D6E2897FCD8</gtr:id><gtr:title>Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05192395343504676076a1c822caa40c"><gtr:id>05192395343504676076a1c822caa40c</gtr:id><gtr:otherNames>Wallis CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>P1vwKwprueR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F56EBA80-2FB0-4504-9B4E-948C7A2FFDAC</gtr:id><gtr:title>Haematological and biochemistry laboratory abnormalities associated with splenomegaly in asymptomatic adults in Masaka, Uganda: implications for HIV biomedical prevention trials.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c49b143941eab24018db8cab075e832"><gtr:id>1c49b143941eab24018db8cab075e832</gtr:id><gtr:otherNames>Ruzagira E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>sJnrzdoqBJK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97845252-982F-49BF-A572-41F0BA61FF07</gtr:id><gtr:title>Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.</gtr:title><gtr:parentPublicationTitle>Human vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2903ac1a2279b57933b759e32d6f3b62"><gtr:id>2903ac1a2279b57933b759e32d6f3b62</gtr:id><gtr:otherNames>Hara H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1554-8600</gtr:issn><gtr:outcomeId>WSBA8FjMqR7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E363DBD1-9EB5-45A7-9ECC-67BBE6808202</gtr:id><gtr:title>Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>VLT4erDCHkC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECD765F4-F8C0-405F-86BB-8F5811B8B2F5</gtr:id><gtr:title>Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/642cb9a312ab04364a2983c4f9f6c49f"><gtr:id>642cb9a312ab04364a2983c4f9f6c49f</gtr:id><gtr:otherNames>Karita E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>F1A33BA8B80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB7B2E57-29AF-4F1E-AD3E-9C86286FE9AB</gtr:id><gtr:title>Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>RPpPmsFXkAV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAB3B705-CB38-42FF-ABD4-9B43CB1C2BF0</gtr:id><gtr:title>PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>rzJyFxQV1Gp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD43EFFB-FDAD-4288-AF56-50E98426AC23</gtr:id><gtr:title>Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d55768d6cb7453a96823795351486cbf"><gtr:id>d55768d6cb7453a96823795351486cbf</gtr:id><gtr:otherNames>Steen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>52AC5BE63E1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE270B5C-AD6B-48A6-96ED-CA264030006D</gtr:id><gtr:title>The role of community acceptance over time for costs of HIV and STI prevention interventions: analysis of the Masaka Intervention Trial, Uganda, 1996-1999.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/364ab0bf33d0f2d36b2c959760be9d42"><gtr:id>364ab0bf33d0f2d36b2c959760be9d42</gtr:id><gtr:otherNames>Terris-Prestholt F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>B785EE881D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5052FA24-585B-4D74-8D5F-9166D7F7243C</gtr:id><gtr:title>HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b1d4a56327da023eec14c05d69572b2"><gtr:id>1b1d4a56327da023eec14c05d69572b2</gtr:id><gtr:otherNames>Asiki G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>omssw1fdMQp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E007048-7B1F-4756-BAEA-16D2B985102B</gtr:id><gtr:title>Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c49b143941eab24018db8cab075e832"><gtr:id>1c49b143941eab24018db8cab075e832</gtr:id><gtr:otherNames>Ruzagira E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>E0E65D10FDB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FC5AEBC-E67B-49C6-BEAE-5A2AE1CE86B7</gtr:id><gtr:title>CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/642cb9a312ab04364a2983c4f9f6c49f"><gtr:id>642cb9a312ab04364a2983c4f9f6c49f</gtr:id><gtr:otherNames>Karita E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>1F1D6F66F0C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87FE36E8-2DC6-4C5B-A57A-E757E9805140</gtr:id><gtr:title>What is new in HIV/AIDS research in developing countries?</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21a3448ce66ad1b34fedc9090711c087"><gtr:id>21a3448ce66ad1b34fedc9090711c087</gtr:id><gtr:otherNames>Kamali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>LMUvtrNa8G6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F03DDFAF-9C09-4C07-9707-D3435C572E11</gtr:id><gtr:title>A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21a3448ce66ad1b34fedc9090711c087"><gtr:id>21a3448ce66ad1b34fedc9090711c087</gtr:id><gtr:otherNames>Kamali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>DceQTHgUXAS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE08D0F5-7FBC-4C9B-A4B6-8ABAD5E70E7B</gtr:id><gtr:title>Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c49b143941eab24018db8cab075e832"><gtr:id>1c49b143941eab24018db8cab075e832</gtr:id><gtr:otherNames>Ruzagira E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>s6SgJBWEC4p</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>166436E9-C5C8-4C87-A345-CC14E2773377</gtr:id><gtr:title>AIDS vaccines and preexposure prophylaxis: is synergy possible?</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be58271950a01d910fabe9e8d6b0abd0"><gtr:id>be58271950a01d910fabe9e8d6b0abd0</gtr:id><gtr:otherNames>Excler JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>iSiiWYcELkT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>551B00F1-602B-449A-BADB-FC6A84638C9F</gtr:id><gtr:title>The role of partnership dynamics in determining the acceptability of condoms and microbicides.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/394b72a586ff4088949765d860a0fe1b"><gtr:id>394b72a586ff4088949765d860a0fe1b</gtr:id><gtr:otherNames>Montgomery CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>6746CED0FF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>460FADA4-F640-490C-AD86-48C063194090</gtr:id><gtr:title>Use of nail and oral pigmentation to determine ART eligibility among HIV-infected Ugandan adults.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a812e4f1abe545f9b5ed7c881ce39f76"><gtr:id>a812e4f1abe545f9b5ed7c881ce39f76</gtr:id><gtr:otherNames>Namakoola I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>tYVrHWy41oY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F50A58D-63F4-48B6-B9A6-0596FC284123</gtr:id><gtr:title>Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f266c5de1e93507f08d86a8b7da2032d"><gtr:id>f266c5de1e93507f08d86a8b7da2032d</gtr:id><gtr:otherNames>Tang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>WaWp24vuAAV</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U950080930</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>